This meta-analysis addresses the efficacy and safety of tixagevimab-cilgavimab as pre-exposure prophylaxis against COVID-19 in immunocompromised patients, particularly during the Omicron variant surge.
Given the limited vaccine response in this population, alternative prophylactic strategies are critical.
